Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has announced positive results from its BRACELET-1 study for the pelareorep-based combination therapy in treating HR+/HER2- advanced or metastatic breast cancer, with significant improvements in overall survival rates and progression-free survival compared to chemotherapy alone. These findings bolster the company’s plans to secure funding for a pivotal registration-enabling study. The therapy’s potential was highlighted by the fact that over half of the patients treated with pelareorep were alive at the study’s conclusion, outperforming the control group.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
